Adult Pneumococcal Disease: Know Your Options | Interactive Multimedia Portal With Practice Tools

Activity Overview

Please read the following information about this CME activity before accessing the Expert Panel Roundtable modules using the link below.

Release Date: Tuesday, February 7, 2012        Expiration Date: Thursday, February 7, 2013

Statement of Need

Pneumococcal bacteria are a leading cause of infectious disease in the United States. Adults are particularly vulnerable to invasive pneumococcal disease that is associated with significant morbidity and mortality. These infections also place a heavy financial burden on the healthcare system due to frequent and prolonged hospitalization. The clinical and economic costs attributed to these infections are expected to increase due to the aging of the US population and increased longevity of patients with immunosuppressive conditions. This is despite the availability of effective preventive measures, such as vaccination, that are critical in maintaining quality of life in the adult patient population, especially in the era of multidrug resistance.

Role of Infectious Diseases Experts

The recent advances in the development of pneumococcal vaccines are anticipated to result in updated immunization recommendations. Healthcare providers (HCPs) must be aware of the latest developments in order to incorporate updated recommendations into their clinical practice. Infectious disease experts will be responsible for providing guidance to HCPs on the appropriate use of vaccines for various adult patient populations based on the available evidence. The recommendations from these experts will assist HCPs in reducing the burden of pneumococcal disease.

Role of Primary Care Providers

Adults at risk for pneumococcal disease commonly present at the offices of their primary care providers (PCPs) with complex healthcare issues, including acute and chronic illnesses and comorbid conditions. Therefore, by being on the forefront of patient care, PCPs can play a significant role in preventing and reducing pneumococcal disease.

Education is critical to close the existing practice gaps. To improve pneumococcal vaccination rates among adults at risk for pneumococcal disease, HCPs must have the competence to:

HCPs must take a more proactive approach in helping to close the pneumococcal immunization gap.

Education Format

This interactive online activity presents the views of leading experts in pneumococcal disease and prevention. Participants have the flexibility to navigate through the program to view evidence-based presentations and faculty discussions on various topics and issues related to pneumococcal disease and immunization. Additional resources and practice tools are available to complement participant learning on these various issues.

Target Audience

This activity is designed for healthcare professionals who manage adult populations at risk for pneumococcal disease and can take a proactive role in preventing these infections through vaccination.

Learning Objectives

When considering pneumococcal prevention in adults, primary care providers play a major role in screening and vaccinating patients at risk. Based on the established educational need, the following learning objectives for HCPs have been established. Upon completing the activity, learners will be able to:


William Schaffner, MD
President, National Foundation for Infectious Diseases
Professor and Chair
Department of Preventive Medicine
Vanderbilt University School of Medicine
Nashville, TN

View Bio

Dr. William Schaffner is Chairman of the Department of Preventive Medicine as well as Professor of Infectious Diseases in the Department of Medicine at the Vanderbilt University School of Medicine, Nashville, Tennessee. His primary interests are infectious diseases and their prevention. Dr. Schaffner has worked extensively on the effective use of vaccines in both pediatric and adult populations.

Currently, Dr. Schaffner is a liaison member of the Advisory Committee on Immunization Practices (ACIP), a former member of the National Vaccine Advisory Committee (NVAC), and a member of the Physician Advisory Board of the Adult Immunization Initiative of the American College of Physicians. He is also a consultant in public health policy and communicable disease control of numerous national and local institutions, including the Centers for Disease Control and Prevention, the World Health Organization, the Tennessee Department of Health, and the American College of Physicians, among others. Dr. Schaffner is a member of numerous professional societies and has written over 400 scientific articles and textbook chapters.

After graduation from Yale in 1957, Dr. Schaffner attended the University of Freiburg, Germany as a Fulbright Scholar. In 1962, he graduated from Cornell University Medical College and then did an internship, residency training, and a Fellowship in Infectious Diseases at Vanderbilt University Medical Center. He was commissioned in the U.S. Public Health Services as an Epidemic Intelligence Service Officer with the Centers for Disease Control in Atlanta for two years (1966-1968). He returned to Vanderbilt after that tour of duty.

Close Bio

Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
President-elect, National Foundation for Infectious Diseases
Chair, Division of Infectious Disease
Summa Health System
Akron, OH
Professor, Internal Medicine; Master Teacher; Chair, Infectious Disease Section
Northeast Ohio Medical University
Rootstown, OH

View Bio

Dr. Thomas M. File, Jr. is Chair of the Infectious Disease Division and Director of HIV Research at Summa Health System in Akron, Ohio, and Professor of Internal Medicine, Master Teacher, and Chair of the Infectious Disease Section at the Northeast Ohio Medical University in Rootstown, Ohio. After graduating from medical school at the University of Michigan, Ann Arbor, in 1972, Dr. File received his Master of Science in medical microbiology from Ohio State University in Columbus, in 1977, where he also completed his fellowship in infectious diseases.

Dr. File is a Master of the American College of Physicians, a Fellow and past-member of the Board of Directors of the Infectious Diseases Society of America (IDSA), and a fellow of the American College of Chest Physicians. He is President-elect of the Board of Directors of the National Foundation for Infectious Diseases and is a member of many other professional societies, including the American Society for Microbiology, the American Thoracic Society (ATS), and the American Society of Hospital Epidemiologists. He is the past Chairperson of the Standards and Practice Guidelines Committee of the IDSA and has also served as a member of the IDSA and ATS committees for guidelines on community-acquired pneumonia; and is a member of the IDSA guidelines panels for hospital-acquired pneumonia, influenza, and sinusitis. He is a past-president of the Infectious Disease Society of Ohio, and is a past-president of the Northeastern Ohio Task Force on AIDS.

Primary research interests that Dr. File has pursued include community-acquired respiratory tract infections, immunizations in adults, bacterial resistance in respiratory infections, infections in patients with diabetes, soft tissue infections, and evaluation of new antimicrobial agents. A frequent lecturer both nationally and internationally, Dr. File has published more than 200 articles, abstracts, and textbook chapters, focusing on the diagnosis, etiology, and treatment of infectious diseases, especially on respiratory tract infections. He co-authored File TM Jr. and Stevens DL Contemporary Diagnosis and Management of Skin and Soft Tissue Infections, 2nd Ed (2007, published by Handbooks in Health Care Co.) and co-edited Tan JS, File TM Jr., Salata RA, Tan MJ (eds.) Expert Guide to Infectious Diseases, 2nd edition (2008, published by ACP Press, Phil.). In addition, he is Editor-in-Chief of Infectious Diseases in Clinical Practice. Dr. File is listed in Best Doctors in America (1996 to present) and Marquis Who's Who in America, 65th Ed. 2011.

Close Bio

Michael D. Hogue, PharmD, FAPhA
Associate Professor and Chair
Department of Pharmacy Practice
Samford University's McWhorter School of Pharmacy
Birmingham, AL

View Bio

Dr. Michael D. Hogue is Chair and Associate Professor of Pharmacy Practice at Samford University's McWhorter School of Pharmacy in Birmingham, AL. He has practice experience in family medicine and community pharmacy, and public health. Dr. Hogue is one of the faculty members responsible for the creation of the first accredited post-graduate residency program in pharmacy with emphasis in public health.

Dr. Hogue received his BS and Pharm.D. degrees from Samford University in Birmingham, and then completed an Executive Residency in Association Management with the American Pharmacists Association (APhA) in Washington, DC. He has authored numerous manuscripts, book chapters and books, including The Pharmacists Guide to Compensation for MTM Services. He has devoted much of his practice and research efforts in the area of immunizations and social factors which influence vaccine decisions.

Dr. Hogue was on the original development team for APhA's Pharmacy-Based Immunization Delivery certificate training program, which has now provided advanced education for over 100,000 pharmacists in the subject. Dr. Hogue is the national President of APhA's Academy of Pharmacy Practice and Management and a member of APhA's Board of Trustees. He is the past chair of the Academy of Pharmacy Practice and Board Member of the Alabama Pharmacy Association. He is a Fellow of APhA, and in 2012 he was named as a Distinguished Practitioner and Fellow of the National Academies of Practice. In addition to APhA, Dr. Hogue is an active member of the American Society of Health-System Pharmacists, the National Community Pharmacists Association, and the American Association of Colleges of Pharmacy.

Close Bio

Kristin L. Nichol, MD, MPH, MBA
Associate Chief of Staff for Research
Minneapolis VA Medical Center
Professor of Medicine, University of Minnesota
Minneapolis, MN

View Bio

Dr. Kristin L. Nichol is Professor of Medicine at the University of Minnesota and Associate Chief of Staff for Research at the VA Medical Center in Minneapolis. Dr. Nichol's research has focused on issues relating to adults vaccines with a special emphasis on influenza and pneumococcal vaccination. She has pursued observational studies and clinical trials in such areas as successful delivery strategies, determinants of vaccination behavior, side effects associated with vaccination, and the clinical efficacy and cost effectiveness of vaccination. Dr. Nichol has authored more than 100 publications in these areas and has given presentations at numerous national and international meetings.

Dr. Nichol is Chairperson of the Minnesota Coalition for Adult Immunization – a position she has held for 20 years. This group provides leadership for enhancing adult vaccination for the entire state of Minnesota. She also served for 15 years as the Department of Veterans Affairs ex officio member of the US Advisory Committee on Immunization Practices (ACIP).

Dr. Nichol received her MD and MPH degrees from the University of Minnesota and her MBA from the University of St. Thomas. She pursued her internal medicine training at the University of California in San Francisco and the University of Minnesota. Dr. Nichol is board certified in Internal Medicine and Preventive Medicine.

Close Bio



This activity has been planned and implemented in accordance with the Essential Areas and Elements and Accreditation Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the National Foundation for Infectious Diseases (NFID) and Vemco MedEd, LLC. The National Foundation for Infectious Diseases is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NFID designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Instruction for Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

For questions, please contact us at


This activity is jointly sponsored by

NFID      and      Vemco MedEd, LLC


As an organization accredited by the Accreditation Council for Continuing Medical Education, it is the policy of NFID to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All individuals in a position to control the content of the activity have disclosed all relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and/or with any commercial supporters of the activity. Disclosure information is reviewed in advance to manage and resolve any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.

Please note that this activity was recorded prior to FDA approval of Pneumococcal 13-Valent Vaccine for adults 50 years and older.


William Schaffner, MD serves as a consultant/advisor for Pfizer Inc., Novartis, Sanofi-Pasteur, GlaxoSmithKlein, Dynavax, and Merck & Co., Inc.

Thomas M. File, Jr., MD serves as a consultant/advisor for Astellas/Theravance, Cerexa/Forest, DaiichiSankyo, GlaxoSmithKlein, Merck & Co., Inc., Nabriva, Pfizer Inc., and Tetraphase. He has received grant/research support from Cempra, Pfizer Inc., and The Medicines Company.

Michael D. Hogue, PharmD serves as a consultant/advisor for Pfizer Inc. and as a speaker for Merck & Co., Inc.

Kristin L. Nichol, MD serves as a consultant/advisor for GlaxoSmithKlein, MedImmune, Merck & Co., Inc., and Novartis.

Planning Committee Members

Len Novick (NFID) owns stock, stock options, or bonds from Cubist, Novavax, Pfizer Inc., and ViroPharma.

Marla Dalton (NFID) has no relevant financial relationships to disclose.

Susan J. Rehm, MD (NFID) serves as an advisor or consultant for Merck & Co., Inc. and Pfizer Inc. and as a speaker for Genentech.

All other employees of NFID and Vemco MedEd have no relevant financial relationships to disclose.


The opinions expressed in this educational activity are those of the faculty and do not reflect the views of NFID and Vemco MedEd. This educational activity may discuss off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States Food and Drug Administration (FDA). NFID and Vemco MedEd do not recommend the use of any product/procedure outside of the labeled indications. A qualified healthcare professional should be consulted before using any therapeutic product/procedure discussed. Clinicians should verify all information and data before treating patients or employing any therapies described in this continuing education activity. Please refer to the prescribing information for each product/procedure for approved indication, contraindications, and warnings.


There is no fee to participate in this activity.

System/Hardware Requirements

Web Browser

Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome
Note: Please disable any "pop-up blocker" features.


Adobe Reader 7 or above to view PDF files (Free download)
Adobe Flash Player 10 or above to view multimedia content (Free download)

Connection Speed

Cable, DSL, or better of at least 300 Kbps

System Check

Please e-mail any questions or concerns to

Copyright Statement

Copyright© 2012 Vemco MedEd, LLC and the National Foundation for Infectious Diseases. All Rights Reserved.

Privacy Policy

Commercial Support

This activity is supported by an educational grant to the National Foundation for Infectious Diseases
from Merck & Co., Inc.

Merck & Co., Inc.

Launch Presentation

By clicking on the Launch Expert Roundtable, I acknowledge that I have read the entire CME information.

Launch Expert Roundtable